Streetbeat News

Analyst Ratings

PAVM

Ascendiant Capital's analyst Edward Woo maintains a Buy rating on PAVmed but lowers the price target from $22 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 9:31 am

ORCL

Piper Sandler analyst Brent Bracelin maintains an Overweight rating on Oracle and raises the price target from $150 to $175.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 9:08 am

CGNT

Cognyte Software Ltd. (NASDAQ:CGNT) is set to release its Q2 earnings, with analysts expecting a smaller loss compared to last year. The company is projected to post $83.69 million in revenue. Recent analyst ratings show mixed sentiments, with some raising price targets.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 8:57 am

AAPL

AMZN

GOOG

GOOGL

META

MSFT

NVDA

TSLA

Bank of America advises investors to avoid increasing exposure to the tech sector due to market volatility and election-related policy uncertainty. Instead, they recommend focusing on defensive stocks for quality, stability, and income. The bank remains underweight on Information Technology, citing overvaluation and potential passive selling pressure due to changes in S&P 500 index-cap rules.

Portfolio Pulse from Benzinga Neuro

September 10, 2024 | 8:56 am

PLAY

Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) is set to release its Q2 earnings on September 10, with expectations of improved earnings per share and revenue. Despite a recent drop in share price, analysts have adjusted their ratings and price targets, reflecting mixed sentiments.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 6:15 am

AVSC

BMI

FN

IWM

PSCT

SPSC

VTWO

Paul Eitelman from Russell Investments highlights opportunities in small-cap stocks, particularly in banks, technology, and highly indebted companies, as interest rates decline. He advises focusing on stock selection over broad sector bets. ETFs like IWM, VTWO, AVSC, and PSCT track small-cap indices.

Portfolio Pulse from Surbhi Jain

September 09, 2024 | 9:29 pm

ABBV

AbbVie (NYSE:ABBV) has seen a surge in options activity, with a majority of investors adopting a bullish stance. This unusual activity suggests potential significant price movements, with expectations ranging from $150 to $210. Analysts maintain an overweight rating with target prices around $213.5.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 8:15 pm

WMT

Investors are taking a bearish stance on Walmart (WMT) through options trading, with 55% of trades being bearish. Significant options activity suggests a price target range of $40 to $85. Analysts maintain positive ratings with price targets around $80.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 8:15 pm

CVS

CVS Health has seen a mix of bullish and bearish options trades, with a focus on a price range of $50 to $70. Recent analyst ratings have been mixed, with some downgrades. The stock is currently trading at $56.47, down 2.22%.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 8:15 pm

LLY

Eli Lilly (NYSE:LLY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month average price target of $964.46, up from $915.68, with a high estimate of $1125.00. The company shows strong financial performance with significant revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 8:00 pm